Alterity Therapeutics to Present at a Virtual Healthcare Conference
Alterity Therapeutics, a biotechnology firm dedicated to developing treatments for neurodegenerative diseases, has recently announced its participation in an upcoming healthcare virtual conference. The event will shine a spotlight on influential healthcare companies and their innovative approaches to addressing significant health challenges.
Virtual Conference Details
David Stamler, chief executive officer of Alterity Therapeutics, is scheduled to deliver a corporate update during the Bell Potter Healthcare Conference. This virtual format offers a unique opportunity for interested parties to engage with the company and learn about its ongoing projects and advancements.
Timing and Participant Information
The presentation will cater to both Australian and American participants with the following schedule:
Australia Participants:
Date: A specific Wednesday in mid-November
Time: 1:30 p.m. AEDT
United States Participants:
Date: The preceding Tuesday of the same week
Time: 6:30 p.m. Pacific Time and 9:30 p.m. Eastern Time.
Expanding Understanding of Neurodegenerative Diseases
Alterity Therapeutics is focusing its resources on cutting-edge research to produce groundbreaking therapies, primarily targeting Parkinson's disease and similar disorders. They are committed to creating alternative futures for individuals affected by such debilitating conditions.
Significance of ATH434
The company's lead candidate, ATH434, has exhibited promising results in clinical trials, specifically designed to address Multiple System Atrophy (MSA), a formidable Parkinsonian disorder. Recent trial outcomes have showcased ATH434’s efficacy, building optimism for those seeking innovative treatment options. These findings underscore Alterity's position as a key player in the biotechnology sector.
About Alterity Therapeutics Limited
Headquartered in Melbourne, Australia, with operations in San Francisco, Alterity stands at the forefront of advanced biotechnology. Their dedication to researching and developing therapies for neurodegenerative diseases is reflected in their innovative drug discovery platform, which enables them to create patentable compounds aimed at addressing the core issues of neurological disorders.
The company's commitment has been validated by positive trial results for ATH434, which not only demonstrates potential efficacy but also reinforces their strategic direction in drug development. Interested individuals can learn more through their official digital presence.
Company Contacts
Investors:
Remy Bernarda
Investor Relations Advisory Solutions
Email: ir@alteritytx.com
Phone: +1 (415) 203-6386
Media Inquiries:
Casey McDonald
Tiberend Strategic Advisors, Inc.
Email: cmcdonald@tiberend.com
Phone: +1 (646) 577-8520
Frequently Asked Questions
What is Alterity Therapeutics known for?
Alterity Therapeutics specializes in developing treatment options for neurodegenerative diseases, with a strong focus on Parkinson's disease.
When is the Bell Potter Healthcare Conference?
The conference will occur mid-November, with separate timings for Australian and American audiences.
Who will be presenting at the conference?
David Stamler, the CEO of Alterity Therapeutics, will present a corporate update during the event.
What are the key focuses of Alterity's research?
The company primarily focuses on therapies aimed at Parkinson's disease and related disorders, including its leading candidate, ATH434.
How can I learn more about Alterity Therapeutics?
For more information, visit Alterity’s official website or reach out through their investor relations email.
